THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) As per available information, there is only one formulation, namely, Garion Tablets which is based on Phenobarbitone Sodium. The price of this formulation was fixed on 19-8-1989 under DPCO, 1987. While fixing the price, landed price of Phenobarbitone Sodium @Rs. 511.01/kg. was taken into account.

(c) Due to price difference between indigenous and imported Phenobarbitone Sodium, IDPL has curtailed its production.

(d) Phenobarbitone Sodium was reserved for public sector way back in 1978. The existing drug policy is presently under review of the Government.

Bulk Drugs produced by IDPL and HAL

3785. CHOWDHARY RAM SEWAK:
SHRI SANTOSH KUMAR SAHU :

Will the PRIME MINISTER be pleased to refer to the answr to Unstarred Question 1313 given in Rajya Sabha on the 5th December, 1991 and state:

(a) what are the bulk drugs produced by IDPL and HAL which are giving them positive contribution and what is the extent of contribution of each;

(b) whether it is a fact that comparative cost of competitors is much lower;

(c) if so, names of drugs which are being produced by other units and are having lower cost of production;

(d) whether any cost-cum-technical study conducted on any of these drugs of these units;

(e) if so, the details thereof;

(f) what are the names of drugs for which technologies were purchased; plants were installed, production was not effected;

(g) that was the cost of each technology and plants and machinery involved in each of these drugs; and

(h) what steps have been taken to prevent wasteful use of raw materials, purchase of substandard raw materials and purchases at high rates?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) The information about contribution, cost of production is of the nature of commercial intelligence and disclosure of such information may not be in the commercial interest of the companies.

(c) There are a number of units manufacturing bulk drugs. The information on capacity, production in the organised sector is a published information and is available in the "Indian Drugs Statistics".

(d) and (e) The Bureau of Industrial Costs and Prices conducts periodical and specific studies of the cost of drugs. The details of cost of production and related matters are commercial information and generally not disclosed.

(f), (g) and (h) Indian Drugs & Pharmaceuticals Ltd. has reported that there were two bulk drugs, namely, Doxycycline & Erythromycin for which the technology was purchased, plants were installed and production subsequently discontinued because of uneconomic cost. The production of Doxycycline and Erythromycin was taken up in 1979-80 and 1980-81 respectively. A part of the equipment has been put to alternative use for production of Ampicillin and for expansion of Penicillin G. Efforts are being made by the company to obtain better industrial strain for Erythromycin. The technology for Erythromycin and Doxycycline was obtained at a total know-how fee of US$ 3.90 lakhs and the value of the plant and machinery (as on 31-3-1990) installed was Rs. 2.19 crores.

Hindustan Antibiotics Ltd. had obtained technology for manufacture of Vitamin C bulk and established production but subsequently discontinued on account of uneconomic cost. The technology was obtained free of cost. The cost of the plant and machinery installed was Rs. 2.65 crores (as on 31-3-1991). The plant and machinery has been put to alternative use. The purchase/procurement of raw materials is made in accordance with the rules and procedures of these Undertakings.